{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:19:44Z","timestamp":1787368784011,"version":"build-2736575974"},"reference-count":16,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2013,9,9]],"date-time":"2013-09-09T00:00:00Z","timestamp":1378684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:p>For the majority of patients with iron deficiency anemia (IDA), a full course of intravenous (IV) iron is 1 g. Most IV irons require 5\u201310 administrations of 100\u2013300 mg. We have successfully employed 1 g low molecular weight iron dextran over 1 hr. For further convenience for patients and physicians, we explored the administration of 1.02 g of ferumoxytol over 15 min instead of the approved 2 \u00d7 510 mg injections. Sixty patients with IDA, (hemoglobin &lt;11 g\/dL, transferrin saturation [TSAT] \u226420%, and ferritin &lt;100 ng\/mL) with an inadequate response or intolerance to oral iron, received 1020 mg ferumoxytol over 15 min. Vital signs were measured for 1 hr. Adverse events (AEs) were collected via telephone at 1, 2, and 7 days. Follow\u2010up visits occurred at 4 and 8 weeks for efficacy assessments. The primary endpoint was safety and tolerability. Secondary efficacy endpoints included mean change in hemoglobin, TSAT, and red cell distribution width. No serious adverse events (SAEs) occurred. Fifty\u2010eight patients received the planned dose. Twenty\u2010six out of sixty (43.3%) patients reported AEs of which 13 were mild and transient during infusion. All resolved within minutes. Fourteen patients reported self\u2010limited arthralgias, myalgias, and\/or headache within 24\u201348 hr. At Baseline, the mean hemoglobin was 9.4 g\/dL. The mean increments at Week 4 and 8 were 2.1 and 2.6 g\/dL, respectively. Ferumoxytol, administered as 1.02 g infusion over 15 min was well tolerated with no SAEs and demonstrated excellent efficacy. If corroborated in future studies this represents an improved method of treating IDA. Am. J. Heamtol. 88:944\u2013947, 2013. \u00a9 2013 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23534","type":"journal-article","created":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T07:58:35Z","timestamp":1373011115000},"page":"944-947","source":"Crossref","is-referenced-by-count":65,"title":["Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min"],"prefix":"10.1002","volume":"88","author":[{"given":"Michael","family":"Auerbach","sequence":"first","affiliation":[{"name":"Auerbach Hematology and Oncology 9110 Philadelphia Road Suite 314 Baltimore Maryland 21237"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Strauss","sequence":"additional","affiliation":[{"name":"AMAG Pharmaceuticals, Inc 100 Hayden Avenue Lexington Massachusetts 02421"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Auerbach","sequence":"additional","affiliation":[{"name":"Auerbach Hematology and Oncology 9110 Philadelphia Road Suite 314 Baltimore Maryland 21237"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Rineer","sequence":"additional","affiliation":[{"name":"Auerbach Hematology and Oncology 9110 Philadelphia Road Suite 314 Baltimore Maryland 21237"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzefa","family":"Bahrain","sequence":"additional","affiliation":[{"name":"Auerbach Hematology and Oncology 9110 Philadelphia Road Suite 314 Baltimore Maryland 21237"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,9]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"279","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","author":"Global Outcomes (KDIGO) Anemia Work Group","year":"2012","journal-title":"Kidney Inter Suppl"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.28587"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02130.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00248.2010"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2011.03.016"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.338"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1980.03300430028018"},{"key":"e_1_2_5_9_1","first-page":"566","article-title":"Clinical use of the total dose intravenous infusion of iron dextran","volume":"111","author":"Auerbach M","year":"1988","journal-title":"J Lab Clin Med"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v31.pm9428456"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01401.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22153"},{"key":"e_1_2_5_13_1","article-title":"Ferumoxytol treatment results in robust hemoglobin increases in iron deficiency anemia patients with a history of unsatisfactory oral iron therapy in a phase III, randomized, placebo\u2010controlled trial","volume":"120","author":"Raj SV","year":"2012","journal-title":"Blood"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.2099.2099"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23322"},{"key":"e_1_2_5_16_1","article-title":"Safety of a single administration of 1 gram of IV ferumoxytol in hemodialysis patients with iron deficiency anemia (IDA) [Abstract PUB\u2010393]","volume":"21","author":"Sabau D","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22249"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23534","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23534","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23534","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.23534","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T14:55:54Z","timestamp":1692543354000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,9]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1002\/ajh.23534"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23534","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,9]]}}}